 Emergent BioSolutions Inc. EBS, 3.55 said Thursday that it began dosing participants in a Phase 1 clinical trial for its universal influenza vaccine candidate. The randomized, double-blind, placebo-controlled dose-escalation study is being conducted in Australia; 60 healthy adults will be enrolled in the study. 